 Connection
Allison Wheeler to Hemophilia B
This is a "connection" page, showing publications Allison Wheeler has written about Hemophilia B.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.050 |
|
|
|
-
Wheeler AP, Abraham A, Barnes C, Brown Frandsen R, d'Oiron R, Eichler H, Hampton K, López-Jaime FJ, Lyu CJ, Tavares CMM, Nogami K, Sutton C, Windyga J, Zulfikar B, Castaman G. Real-World Unmet Needs of Patients With Haemophilia A and Haemophilia B With or Without Inhibitors: End-of-Study Results From the explorer6 Non-Interventional Study. Haemophilia. 2025 Sep; 31(5):903-911.
Score: 0.853
-
Buckner TW, Kessler C, Castaman G, Hermans C, Jiménez-Yuste V, Mahlangu J, Miesbach W, Oldenburg J, Recht M, Valentino LA, Wheeler AP, Pipe SW. Pain Reduction Following Eptacog Beta Treatment of Bleeding Episodes in Adolescents and Adults With Haemophilia A or B Complicated by Inhibitors. Haemophilia. 2025 Jul; 31(4):713-721.
Score: 0.215
-
Chowdary P, Angchaisuksiri P, Apte S, Astermark J, Benson G, Chan AKC, Jiménez Yuste V, Matsushita T, Høgh Nielsen AR, Sathar J, Sutton C, ?aulyte Trakymiene S, Tran H, Villarreal Martinez L, Wheeler AP, Windyga J, Young G, Thaung Zaw JJ, Eichler H. Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial. Lancet Haematol. 2024 Dec; 11(12):e891-e904.
Score: 0.206
-
Pipe SW, Leebeek FWG, Recht M, Key NS, Castaman G, Miesbach W, Lattimore S, Peerlinck K, Van der Valk P, Coppens M, Kampmann P, Meijer K, O'Connell N, Pasi KJ, Hart DP, Kazmi R, Astermark J, Hermans CRJR, Klamroth R, Lemons R, Visweshwar N, von Drygalski A, Young G, Crary SE, Escobar M, Gomez E, Kruse-Jarres R, Quon DV, Symington E, Wang M, Wheeler AP, Gut R, Liu YP, Dolmetsch RE, Cooper DL, Li Y, Goldstein B, Monahan PE. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B. N Engl J Med. 2023 02 23; 388(8):706-718.
Score: 0.183
-
Shapiro AD, Angchaisuksiri P, Astermark J, Benson G, Castaman G, Eichler H, Jiménez-Yuste V, Kavakli K, Matsushita T, Poulsen LH, Wheeler AP, Young G, Zupancic-?alek S, Oldenburg J, Chowdary P. Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors. Blood Adv. 2022 06 14; 6(11):3422-3432.
Score: 0.175
-
Shapiro AD, Angchaisuksiri P, Astermark J, Benson G, Castaman G, Chowdary P, Eichler H, Jiménez-Yuste V, Kavakli K, Matsushita T, Poulsen LH, Wheeler AP, Young G, Zupancic-Salek S, Oldenburg J. Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. Blood. 2019 11 28; 134(22):1973-1982.
Score: 0.146
-
Croteau SE, Cheng D, Cohen AJ, Holmes CE, Malec LM, Silvey M, Thornburg CD, Wheeler AP, Kouides PA, Raffini LJ, Neufeld EJ. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia. Haemophilia. 2019 Jul; 25(4):668-675.
Score: 0.140
-
Sood SL, Cheng D, Ragni M, Kessler CM, Quon D, Shapiro AD, Key NS, Manco-Johnson MJ, Cuker A, Kempton C, Wang TF, Eyster ME, Kuriakose P, von Drygalski A, Gill JC, Wheeler A, Kouides P, Escobar MA, Leissinger C, Galdzicka S, Corson M, Watson C, Konkle BA. A cross-sectional analysis of cardiovascular disease in the hemophilia population. Blood Adv. 2018 06 12; 2(11):1325-1333.
Score: 0.132
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|